Patent intelligence · US
US 2021315993
PHOTODYNAMIC THERAPY COMPRISING TWO LIGHT EXPOSURES AT DIFFERENT WAVELENGTHS
PHOTODYNAMIC THERAPY COMPRISING TWO LIGHT EXPOSURES AT DIFFERENT WAVELENGTHS
Patent details — US 2021315993
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 14, 2021
- Expiration
- Oct 9, 2041
- Applicant
- BIOFRONTERA BIOSCIENCE GMBH [DE]
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 107 A I, A61K 41/ 00 A I, A61K 47/ 10 A I
Quick answer
US 2021315993 (PHOTODYNAMIC THERAPY COMPRISING TWO LIGHT EXPOSURES AT DIFFERENT WAVELENGTHS) is held by BIOFRONTERA BIOSCIENCE GMBH [DE]. Status: granted. Granted Oct 14, 2021. Expires Oct 9, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOFRONTERA BIOSCIENCE GMBH [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 107 A I, A61K 41/ 00 A I, A61K 47/ 10 A I, A61K 47/ 24 A I, A61K/410061
More from BIOFRONTERA BIOSCIENCE GMBH [DE]
Related pharmaceutical patents in our USPTO index.
-
US 20260108463
NANOEMULSION FORMULATION WITH IMPROVED TACROLIMUS STABILITY AND SKIN PENETRATION
granted -
US 2024335360
PRESSURIZED NANOEMULSION
granted -
WO 2024209065
NANOÉMULSION SOUS PRESSION
granted -
WO 2024209064
NANOÉMULSION SANS PROPYLÈNE GLYCOL
granted -
US 2024335380
NANOEMULSION WITHOUT PROPYLENE GLYCOL
granted -
WO 2014117863
FORMES POLYMORPHES DE SELS D'ADDITION D'ACIDE DE THIOXANTHÈNE-9-YLIDÈNE-1-MÉTHYLPIPÉRIDINES UTILISÉS COMME COMPOSÉS ANTIMIGRAINEUX
granted -
DE 202010004750
Pharmazeutische oder/und kosmetische Zusammensetzung zur Behandlung der Haut
granted
Frequently asked questions
What is US patent 2021315993?
US 2021315993 (PHOTODYNAMIC THERAPY COMPRISING TWO LIGHT EXPOSURES AT DIFFERENT WAVELENGTHS) is held by BIOFRONTERA BIOSCIENCE GMBH [DE]. Status: granted. Granted Oct 14, 2021. Expires Oct 9, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2021315993?
BIOFRONTERA BIOSCIENCE GMBH [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 13 pharmaceutical patents for this assignee.
When does US 2021315993 expire?
Our index shows an expiration date of Oct 9, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.